Kvika banki hf.
28.1.2021 17:37:39 CET | Globenewswire | Press release
A meeting of the Board of Directors of Kvika banki hf. ("Kvika" or "the bank") on 28 January 2021 approved its operating budget for 2021.
Forecast profit for 2021 of ISK 2,600-3,000 million before tax
The budget anticipates a pre-tax profit in the range of ISK 2,600 to 3,000 million.
The Bank's performance may deviate from this forecast, among other things, due to market conditions and other unforeseen events.
A merger with TM hf. and Lykill fjármögnun hf. is anticipated before the end of Q1 2021. Since the approval of supervisory authorities and shareholders of all parties has not yet been obtained the forecast does not include the anticipated financial effects of the merger. Should the merger be approved the change to the forecast will be considerable. A new forecast will be published after the merger is finalised.
Performance above guidance according to preliminary results
According to preliminary results, Kvika's profit in 2020 is expected to be around ISK 2,340 million before tax. The bank's guidance for 2020 was raised in October to an estimated pre-tax profit of ISK 2,000 to 2,300 million.
Kvika’s Board of Directors will propose to a shareholders’ meeting that no dividends be paid in 2021 for the 2020 operating year. This proposal is submitted in view of the proposed merger. The Board of Directors does intend, however, to request that the bank’s Annual General Meeting grant an authorisation for share buy-backs.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
